VK0214
X-linked adrenoleukodystrophy (X-ALD)
Phase 1bActive
Key Facts
About Viking Therapeutics
Viking Therapeutics leverages its expertise in metabolism to develop innovative therapies for metabolic and endocrine disorders. The company's most advanced program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 trials for obesity, with promising Phase 2 data showing significant weight reduction. Viking is also developing VK2809 for lipid disorders and maintains a broader pipeline including VK0214 and VK5211, positioning itself as a key player in the competitive metabolic disease space.
View full company profile